Type 2 DM is a worldwide endemic disease. Dyslipidemia is also a frequent disorder associated with diabetic patients. Lipid profiles can vary in distinct ethnic groups and population. There have been few trials about lipoprotein a (Lpa) levels in type 2 diabetic patients. We investigated serum lipid profiles, Lpa levels and metabolic syndrome findings in type 2 diabetic patients. In this prospective trial, 709 type 2 diabetic patients (407 F; 302 M) and 157 healthy control subjects (91F; 66M) living in the same geographic region were included. The mean age of patients was 53.4 ± 9.2 years. After 12-h overnight fasting, blood samples were obtained for analyzing the serum lipids. The serum total cholesterol, HDL, LDL, and triglycerides levels were measured by glucose enzymatic calorimetric method and apo-B, lipoprotein (a) levels by electrochemiluminescence Immunoassay. All patients were also evaluated for metabolic syndrome by NCEP ATP III criteria. Type 2 diabetic patients had higher serum total cholesterol, LDL cholesterol, triglyceride and apo-B levels and lesser HDL-cholesterol, compared with the control group (p<0.001). The serum Lpa was found to be similar in both type 2 diabetic and control subjects (p=0.519). Of the 709 diabetic patients, 516 (72.9%) had metabolic syndrome. In conclusion, as expected, dyslipidemia and metabolic syndrome was found to be higher in diabetic patients with respect to healthy controls, however, serum Lpa levels were not different in both groups.

Keywords:
Diabetes Mellitus, lipid profiles, Lipoprotein (a), metabolic syndrome
This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2010
You do not currently have access to this content.